- Home
- Publications
- Publication Search
- Publication Details
Title
Antibody-drug conjugates—an emerging class of cancer treatment
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 114, Issue 4, Pages 362-367
Publisher
Springer Nature
Online
2016-01-08
DOI
10.1038/bjc.2015.435
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Site-Specific Antibody–Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development
- (2015) Paresh Agarwal et al. BIOCONJUGATE CHEMISTRY
- Antibody-targeted drugs and drug resistance—Challenges and solutions
- (2015) LeeRon Shefet-Carasso et al. DRUG RESISTANCE UPDATES
- Update on Metastatic Gastric and Esophageal Cancers
- (2015) Manish A. Shah JOURNAL OF CLINICAL ONCOLOGY
- Antibody–drug conjugates—A new wave of cancer drugs
- (2014) Hervé Bouchard et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Trastuzumab emtansine: mechanisms of action and drug resistance
- (2014) Mark Barok et al. BREAST CANCER RESEARCH
- Curative Properties of Noninternalizing Antibody-Drug Conjugates Based on Maytansinoids
- (2014) E. Perrino et al. CANCER RESEARCH
- Development of Novel ADCs: Conjugation of Tubulysin Analogues to Trastuzumab Monitored by Dual Radiolabeling
- (2014) R. Cohen et al. CANCER RESEARCH
- The Next Generation of Antibody Drug Conjugates
- (2014) Fiona Mack et al. SEMINARS IN ONCOLOGY
- Radioimmunoconjugates for the Treatment of Cancer
- (2014) Françoise Kraeber-Bodéré et al. SEMINARS IN ONCOLOGY
- A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
- (2013) S. H. Petersdorf et al. BLOOD
- Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy
- (2013) G. D. L. Phillips et al. CLINICAL CANCER RESEARCH
- Antibody–drug conjugates: current status and future directions
- (2013) Heidi L. Perez et al. DRUG DISCOVERY TODAY
- Use of Statins and the Risk of Death in Patients With Prostate Cancer
- (2013) Oriana Yu et al. JOURNAL OF CLINICAL ONCOLOGY
- Site-specific antibody drug conjugates for cancer therapy
- (2013) Siler Panowski et al. mAbs
- Maturing antibody–drug conjugate pipeline hits 30
- (2013) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- Monoclonal antibody-based therapies in cancer: Advances and challenges
- (2013) Puja Sapra et al. PHARMACOLOGY & THERAPEUTICS
- Antibody-Drug Conjugates in Cancer Therapy
- (2012) Eric L. Sievers et al. Annual Review of Medicine
- Antibody-Drug Conjugates for the Treatment of Cancer
- (2012) John A. Flygare et al. Chemical Biology & Drug Design
- Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
- (2012) Barbara Pro et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Antibody–drug conjugates: Basic concepts, examples and future perspectives
- (2012) Giulio Casi et al. JOURNAL OF CONTROLLED RELEASE
- Therapeutic Potential of Amanitin-Conjugated Anti-Epithelial Cell Adhesion Molecule Monoclonal Antibody Against Pancreatic Carcinoma
- (2012) Gerhard Moldenhauer et al. JNCI-Journal of the National Cancer Institute
- Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
- (2012) Sylvie Castaigne et al. LANCET
- Long-term Tumor Regression Induced by an Antibody-Drug Conjugate That Targets 5T4, an Oncofetal Antigen Expressed on Tumor-Initiating Cells
- (2012) P. Sapra et al. MOLECULAR CANCER THERAPEUTICS
- The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
- (2012) Peter D Senter et al. NATURE BIOTECHNOLOGY
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- (2012) Marco Gerlinger et al. NEW ENGLAND JOURNAL OF MEDICINE
- A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels
- (2011) A Palumbo et al. BRITISH JOURNAL OF CANCER
- SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies
- (2011) V. Blanc et al. CLINICAL CANCER RESEARCH
- Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2-Positive Cancer
- (2011) P. M. LoRusso et al. CLINICAL CANCER RESEARCH
- Antibody Conjugate Therapeutics: Challenges and Potential
- (2011) B. A. Teicher et al. CLINICAL CANCER RESEARCH
- Investigational antibody drug conjugates for solid tumors
- (2011) Puja Sapra et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
- (2010) Teemu T. Junttila et al. BREAST CANCER RESEARCH AND TREATMENT
- Antibody–drug conjugates for cancer: poised to deliver?
- (2010) Bethan Hughes NATURE REVIEWS DRUG DISCOVERY
- Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas
- (2009) H.-P. Gerber et al. BLOOD
- A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability
- (2009) B ten Cate et al. LEUKEMIA
- Cancer stem cells: mirage or reality?
- (2009) Piyush B Gupta et al. NATURE MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now